Q3 Particle-Size-Distribution Sameness

Compare the particle-size distribution of a test topical / in-vitro product against the reference (RLD). Primary verdict: Population Bioequivalence (PBE) on D50 and SPAN — 95% upper bound ≤ 0 by the FDA modified-large-sample method (Hyslop– Hsuan–Holder 2000). For complex/multimodal profiles the Earth Mover's Distance of the full volume curve is reported as supporting context (AAPS J 2018).

1 · Paste your PSD data (CSV)

Two input forms (headers auto-detected):
• Descriptors: product, batch, d10, d50, d90 (one row per batch) — runs PBE on D50 & SPAN.
• Full profile: product, batch, size, volume_pct (many rows per batch) — additionally computes the EMD and derives D10/D50/D90.
The reference is the product labelled rld / ref / reference (or set it above). ≥ 3 test and ≥ 3 reference batches recommended (PBE compares batch populations).

2 · Result

Computational Q3 particle-size-distribution-sameness screening — one component of a Q3 microstructure assessment, not a standalone regulatory certification. The 95% PBE upper bound is the FDA MLS method cross-checked internally by a fixed-seed bootstrap; it is not validated against a commercial evaluator. Not medical or regulatory advice; the overall Q3 / bioequivalence decision is the responsibility of the user's regulatory team.